ClinicalTrials.gg
RecruitingNCT07620041Updated Sep 15, 2026

Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

A Phase 1 interventional study of QLC5508 (Investigational Product / Formulation T) and QLC5508 (Reference Product / Formulation R) in Refractory or Relapsed Solid Tumors, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A clinical trial of QLC5508 for advanced solid tumors

The goal of this clinical trial is to learn if QLC5508 can be given safely to adults with advanced solid tumors. It will also learn how two different formulations of QLC5508 compare in the body, and whether other drugs affect QLC5508. The main questions it aims to answer are:

Does a single injection of QLC5508 change the heart's electrical activity (QTc interval)?

How do the test formulation and the reference formulation of QLC5508 compare in the body (pharmacokinetics)?

Do other drugs (itraconazole, darolutamide, or rifampicin) change how the body processes QLC5508?

Investigators will compare the test formulation to the reference formulation, and will also give QLC5508 together with itraconazole, darolutamide, or rifampicin to look for drug-drug interactions.

Participants will:

Receive QLC5508 by injection into a vein;

Join one of three groups: two groups will receive both formulations of QLC5508 at different times (crossover) and also take rifampicin or itraconazole; the third group will take darolutamide with QLC5508;

Have heart monitoring (Holter) during the first dose;

Undergo regular blood tests, safety checks, and immunogenicity testing (to see if the body develops antibodies against QLC5508).

02

Conditions studied

  • Refractory or Relapsed Solid Tumors

Keywords

  • Concentration (c)-QTc
  • Pharmacokinetics
  • Drug-drug interaction
  • Relapsed Solid Tumors
03

In context

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must voluntarily sign the Form (ICF) and demonstrate the capacity to understand and adhere to study requirements.
  • Participants must be ≥18 years of age at the time of signing the ICF, regardless of sex.
  • (ECOG) Performance Status (PS) score of 0 or 1 (refer to Appendix 2).
  • of ≥6 months.
  • or cytologically confirmed advanced malignant solid tumor, with failure of, intolerance to, or absence of standard therapy.
  • According to v1.1, participants must have at least one ; participants with non-target lesions only are allowed.
  • Adequate organ function within 7 days prior to the first dose of the product. (Note: Use of any blood products, cell growth factors, leukocyte/-boosting agents, anemia-correcting drugs, or hepatoprotective treatments is strictly prohibited during this 7-day screening window.):

    1. Hematology: ≥1.5 × 10⁹/L; Platelet count ≥100 × 10⁹/L; ≥90 g/L.
    2. Renal function: Serum creatinine ≤1.5 × (ULN); for participants with creatinine >1.5 × ULN, (CrCl) calculated via the Cockcroft-Gault formula must be ≥60 mL/min.
    3. Hepatic function: Total ≤1.5 × ULN (≤3 × ULN permitted for participants with Gilbert's syndrome; ≤2.5 × ULN permitted for those with liver ). (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (≤5 × ULN permitted for participants with Gilbert's syndrome or liver metastases). Albumin (ALB) ≥25 g/L.
    4. Coagulation: (INR) or Activated Partial Thromboplastin Time (APTT) ≤1.5 × ULN.
  • (LVEF) ≥50%.
  • Recovery from all reversible Adverse Events (AEs) related to prior anti-tumor therapy to ≤Grade 1 (per v6.0), excluding alopecia (any grade) and ≤Grade 2 peripheral neuropathy. Participants with other abnormal findings deemed clinically insignificant or at no safety risk by the Investigator are eligible.
  • Participants of (both female and non-sterilized male) must agree to use reliable methods from the time of signing the ICF until at least 180 days after the last dose of the investigational product (refer to Appendix 3). Sperm or ova donation must be avoided during this period.
  • Female participants of childbearing potential must be non-lactating and have a negative serum pregnancy test within 7 days prior to the first dose.

Exclusion criteria

Exclusion Criteria:

  • Received chemotherapy, biotherapy, immunotherapy, antibodies, ADCs, or other anti-tumor therapies within 4 weeks prior to the first dose of the product. Special circumstances are as follows:

    1. Includes oral fluoropyrimidines, small molecule targeted drugs, endocrine therapy, palliative radiotherapy, or traditional Chinese medicine (TCM) treatments with anti-tumor indications within 2 weeks prior to the first dose;
    2. Includes mitomycin or nitrosourea-based drugs within 6 weeks prior to the first dose;
    3. Includes cell-based therapies or anti-tumor vaccines within 8 weeks prior to the first dose;
  • Presence of uncontrolled or symptomatic Central Nervous System (CNS) , , or spinal cord compression due to metastasis prior to signing the ICF. The following exception applies: Participants with symptomatic who received treatment and have achieved radiological stability for ≥4 weeks (defined as two brain images acquired using the same imaging modality, both collected after CNS metastasis treatment and at least 4 weeks apart, showing no evidence of intracranial progression upon comparison), exhibit no signs of cerebral edema, and have discontinued systemic treatment (at any dose) for >2 weeks prior to the first dose of the investigational product;
  • History of other active within 3 years prior to signing the ICF, except for the following: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, prostatic carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, or other malignancies that have been treated, show no evidence of disease for >2 years, and do not require ongoing treatment;
  • Within 1 week prior to the first dose or within 5 half-lives of using the following drugs (whichever is longer), received strong or moderate inhibitors or inducers of , P-glycoprotein (P-gp), Breast Cancer Resistance Protein (BCRP), or Organic Anion Transporting Polypeptide (OATP1B1); or participants requiring continued treatment with these drugs during the study period in Cycles C1 and C2 (list of drugs provided in Appendix 5);
  • (HIV) positive participants; positive Treponema pallidum antibodies (participants with a negative titer test are allowed); positive Surface Antigen (HBsAg) with Hepatitis B virus Deoxyribonucleic acid (HBV-DNA) ≥2000 IU/mL or 10⁴ copies/mL; positive virus (HCV) antibodies with positive Hepatitis C virus Ribonucleic acid (HCV-RNA) (Note: If HCV-RNA cannot be tested at the study site, results from a qualified tertiary hospital are acceptable);
  • Within 6 months prior to signing the ICF, history of comorbid cardiovascular or cerebrovascular diseases, including but not limited to:

Myocardial infarction, severe/unstable angina, stroke or , myocarditis, congenital heart diseases such as valvular stenosis, regurgitation, and cardiomyopathy; Severe or uncontrolled hypertension, including: history of hypertensive crisis or hypertensive encephalopathy; persistent systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg after optimal treatment; Cardiac insufficiency classified above Class II according to the (NYHA) Functional Classification, as well as participants with clinically significant supraventricular or ventricular arrhythmias; Participants with a mean interval (QTcF) >450 ms (males) or >470 ms (females) on the 12-lead prior to the first dose of the investigational product; Presence of any factors that increase the risk of QTc prolongation or arrhythmic events, such as hypokalemia, congenital long QT syndrome, family history of long QT syndrome, unexplained sudden death in immediate family members under 40 years of age, or concomitant medications that prolong the QT interval (receiving or requiring continued treatment with these medications during the study period);

  • Occurrence of severe arterial or venous thromboembolic events within 3 months prior to the first dose, such as deep vein thrombosis, pulmonary embolism, etc. (Implantable venous access port-related, catheter-induced thrombosis, or superficial venous thrombosis are excluded and not considered "severe" thromboembolism);
  • Received systemic corticosteroids (prednisone >10 mg/day or equivalent doses of similar drugs) or other such as cyclophosphamide, azathioprine, methotrexate, and anti-TNF-α agents within 14 days prior to the first dose; the following exceptions apply: use of topical, ophthalmic, intra-articular, nasal, or inhaled corticosteroids; short-term use of corticosteroids for prophylactic treatment (e.g., prevention of contrast agent allergy);
  • Participated in any other clinical research study and used other investigational products (excluding minerals, vitamins, etc.) within 4 weeks (or unknown half-life) prior to the first dose, or less than 2 weeks (half-life ≤3 days) or less than 28 days (half-life >3 days) from the last dose of the previous investigational product;
  • Known allergy to any components of QLC5508, Itraconazole capsules, Rifampicin capsules, or Darolutamide tablets, or their ; history of severe allergy (such as anaphylactic shock), severe infusion reaction, or allergy to recombinant human or murine protein substances;
  • Presence of other severe physical or psychiatric illnesses, or abnormal laboratory tests that may increase the risk of participating in the study or interfere with the study results, and participants deemed unsuitable for participation by the Investigator.
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Arm 1: Formulation Crossover & drug-drug interaction (DDI) Assessment (Rifampicin/Itraconazole)

    Drug: QLC5508 (Investigational Product / Formulation T) · Drug: QLC5508 (Reference Product / Formulation R) · Drug: Itraconazole · Drug: Rifampicin

  • Experimental
    Arm 2: Formulation Crossover & drug-drug interaction (DDI) Assessment (Rifampicin/Itraconazole)

    Drug: QLC5508 (Investigational Product / Formulation T) · Drug: QLC5508 (Reference Product / Formulation R) · Drug: Itraconazole · Drug: Rifampicin

  • Experimental
    Arm 3: drug-drug interaction (DDI) Assessment (Darolutamide)

    Drug: QLC5508 (Investigational Product / Formulation T) · Drug: Darolutamide

Interventions

  • DrugQLC5508 (Investigational Product / Formulation T)

    Drug page: QLC5508

    Single intravenous (IV) infusion of QLC5508 for pharmacokinetic (PK) and C-QTc assessment in patients with advanced solid tumors.

  • DrugQLC5508 (Reference Product / Formulation R)

    Drug page: QLC5508

    Single IV infusion of QLC5508 for comparative PK evaluation against the investigational formulation.

  • DrugItraconazole

    Multiple oral doses of itraconazole capsules to evaluate the drug-drug interaction (DDI) potential via CYP3A4 inhibition.

  • Multiple oral doses of darolutamide tablets to evaluate the drug-drug interaction (DDI) potential.

  • DrugRifampicin

    Single oral dose of rifampicin capsules to evaluate the DDI potential.

06

What researchers measure

Primary outcomes

  1. The correlation between the plasma concentration of the QLC5508 payload and the change from baseline in the QTc interval (ΔQTc) derived from the concentration-QTc (C-QTc) model.

    Time frame: Time Frame: From baseline to approximately Month 6

  2. Following a single intravenous injection of QLC5508 Formulation T (investigational product) versus Formulation R (reference product), the Cmax of QLC5508

    Time frame: From baseline to approximately Month 6

  3. TheAUC0-t of QLC5508 following single use or co-administration with itraconazole

    Time frame: From baseline to approximately Month 6

  4. The AUC0-∞ of QLC5508 following single use or co-administration with darolutamide

    Time frame: From baseline to approximately Month 6

  5. The Tmax of QLC5508 following single use or co-administration with rifampicin

    Time frame: From baseline to approximately Month 6

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
Jun 2, 2026
StartActual
Jun 9, 2026
Primary completionEst.
Dec 5, 2026
CompletionEst.
Feb 5, 2027
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07620041
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Jun 9, 2026
Primary completion
Dec 5, 2026 (estimated)
Completion
Feb 5, 2027 (estimated)
Last update
Sep 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QLC5508

Start the discussion